RAD34 Antibody

What are the key functional roles of RAD50, RAD51, and RAB34 proteins in cellular processes?

RAD51 plays a critical role in homologous recombination (HR), a fundamental DNA repair mechanism. It binds to single-stranded DNA in an ATP-dependent manner to form nucleoprotein filaments that are essential for homology search and strand exchange between homologous DNA partners . This process forms joint molecules between processed DNA breaks and repair templates, which is crucial for maintaining genomic integrity. Beyond its primary role in DNA repair, RAD51 is recruited to resolve stalled replication forks during replication stress and participates in a PALB2-scaffolded HR complex containing BRCA2 and RAD51C . Additionally, RAD51 contributes to regulating mitochondrial DNA copy number under oxidative stress conditions when working with RAD51C and XRCC3, and is involved in interstrand cross-link repair .

RAD50 functions as part of the MRN complex (MRE11-RAD50-NBS1), which plays crucial roles in double-strand break repair, DNA replication, telomere maintenance, and cell cycle checkpoint activation . The protein is widely expressed across multiple cell types, including various cancer cell lines such as K-562 (chronic myelogenous leukemia lymphoblast), MOLT-4 (lymphoblastic leukemia T lymphoblast), and MCF7 cells .

RAB34 belongs to the RAB family of small GTPases involved in intracellular membrane trafficking and organelle positioning, particularly in the context of lysosomal positioning and macropinocytosis .

How are antibodies against these proteins validated for research applications?

Antibody validation employs multiple complementary techniques to ensure specificity and reproducibility:

For polyclonal antibodies like anti-RAB34, validation typically involves immunohistochemistry (IHC), immunocytochemistry-immunofluorescence (ICC-IF), and Western blotting (WB) . These validation processes assess both specificity (binding to the intended target) and sensitivity (detection at physiologically relevant concentrations).

For monoclonal antibodies like anti-RAD51 (clone EPR4030(3)), validation is more extensive and includes:

• Multi-tissue microarray (TMA) validation to confirm specificity across different tissue types

• Specificity testing across multiple species (human, mouse, rat)

• Application-specific validation in Western blot, IHC, immunofluorescence, and flow cytometry

• Citation validation (e.g., the RAD51 antibody clone EPR4030(3) has been cited in over 210 publications, providing real-world validation)

For recombinant monoclonal antibodies like anti-RAD50 (clone EPR3466(2)), manufacturers typically validate using Western blotting across multiple cell lines to confirm consistent detection at the expected molecular weight (153 kDa predicted vs. 150 kDa observed for RAD50) .

What experimental controls are essential when using these antibodies in research?

When designing experiments with these antibodies, researchers should implement the following essential controls:

• Positive controls: Cell lines or tissues known to express the target protein (e.g., K-562, MOLT-4, Jurkat, and MCF7 for RAD50)

• Negative controls:

  • Primary antibody omission control

  • Isotype control (identical immunoglobulin class but irrelevant specificity)

  • Cell lines with confirmed absence or knockdown of the target protein

• Loading/staining controls:

  • Housekeeping proteins for Western blot normalization

  • Nuclear stains for immunofluorescence localization verification

• Specificity controls:

  • Peptide competition assays to confirm epitope specificity

  • Multiple antibodies targeting different epitopes of the same protein

• Method-specific controls:

  • For Western blotting: Molecular weight markers to confirm band size

  • For immunoprecipitation: Non-specific IgG precipitation control

  • For immunofluorescence: Secondary antibody-only control

How can researchers optimize antibody specificity when studying closely related protein targets?

Optimizing antibody specificity for closely related proteins presents significant challenges, particularly for proteins that share high sequence homology. Recent advances combine experimental selection with computational modeling to address this challenge:

• Biophysical model integration: Implementing biophysics-informed modeling with experimental selection data allows researchers to identify discrete binding modes associated with specific ligands . This approach enables the discrimination of structurally and chemically similar ligands, which is particularly valuable when working with protein families like RAB GTPases or RAD proteins that share structural similarities.

• High-throughput sequencing with machine learning: This combined approach allows researchers to:

  • Disentangle different binding contributions from a single experiment

  • Identify and characterize distinct binding modes associated with specific ligands

  • Predict antibody specificity beyond experimentally tested sequences

• Counter-selection strategies: Computational approaches can efficiently eliminate off-target antibodies by classifying antibody sequences observed in multiple selection experiments . This method is particularly effective for identifying nonspecific antibodies that bind to several potentially unrelated targets.

• Experimental validation of computational predictions: Testing antibody variants predicted by computational models but absent from training sets provides a powerful method to validate specificity optimization approaches .

What factors most significantly affect experimental reproducibility when using these antibodies?

Research reproducibility with antibodies against RAD50, RAD51, and RAB34 is influenced by several critical factors:

• Antibody format and production method:

  • Polyclonal antibodies (like anti-RAB34) may show batch-to-batch variation due to their production in animals

  • Monoclonal antibodies provide better consistency but may still vary between lots

  • Recombinant monoclonal antibodies (like anti-RAD51 and anti-RAD50) offer "unrivaled batch-batch consistency" with "no need for same-lot requests"

• Experimental conditions optimization:

  • Buffer composition (salt concentration, pH, detergents)

  • Incubation parameters (time, temperature)

  • Blocking efficiency (appropriate blocking agents)

• Sample preparation consistency:

  • Cell culture conditions (passage number, confluency)

  • Tissue processing (fixation time, antigen retrieval methods)

  • Protein extraction methods (lysis buffers, protease inhibitors)

• Detection systems:

  • Signal amplification methods

  • Detection reagent quality and consistency

  • Imaging parameters and quantification methods

• Target protein biology:

  • Post-translational modifications affecting epitope accessibility

  • Complex formation potentially masking antibody binding sites

  • Subcellular localization changes affecting accessibility

How can computational approaches enhance antibody specificity prediction and design?

Recent computational approaches have revolutionized antibody specificity prediction and design, as demonstrated in the context of phage display experiments:

• Biophysics-informed modeling: This approach incorporates physical constraints into machine learning models to provide quantitative insights into antibody-antigen interactions . Unlike purely statistical models, biophysics-informed models offer interpretability that enhances our fundamental understanding of protein-protein interactions.

• Multiple binding mode identification: Advanced computational models can associate distinct binding modes with particular ligands, enabling prediction and generation of antibody variants beyond those observed experimentally . This capability is particularly valuable for designing antibodies with:

  • Specific high affinity for a particular target

  • Cross-specificity for multiple selected targets

  • Discrimination between structurally similar epitopes

• Experimental-computational integration: The most powerful approaches combine:

  • Phage display selection experiments against different ligand combinations

  • High-throughput sequencing of selected antibody libraries

  • Computational modeling to disentangle binding modes

  • Experimental validation of computationally designed antibodies

• Practical implementation:

  • Training computational models on experimentally selected antibodies

  • Associating distinct binding modes with each potential ligand

  • Predicting specificity profiles for new antibody sequences

  • Designing novel antibodies with customized specificity profiles

This integrated approach has successfully generated antibodies capable of discriminating between structurally and chemically similar ligands, even when these epitopes cannot be experimentally dissociated from other epitopes present in the selection .

What are the optimal experimental conditions for using these antibodies in Western blotting?

Optimizing Western blot conditions for RAD50, RAD51, and RAB34 antibodies requires attention to several key parameters:

For anti-RAD50 antibody [EPR3466(2)]:

• Dilution: 1/1000 to 1/5000 depending on cell type and detection system

• Sample loading: 10-20 μg total protein per lane

• Expected band size: 153 kDa (predicted), 150 kDa (observed)

• Blocking buffer: 5% non-fat dry milk in TBST

• Detection system: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG

• Cell lines validated: K-562, MOLT-4, Jurkat, MCF7

For anti-RAD51 antibody [EPR4030(3)]:

• Multiple applications validated: Western blotting, IHC, immunofluorescence, flow cytometry

• Species reactivity: Human, mouse, rat

• Epitope specificity: Recognizes full-length RAD51 protein

How should researchers approach antibody selection for studying DNA repair complexes?

When investigating DNA repair complexes involving RAD50, RAD51, or related proteins, researchers should consider:

• Complex-specific considerations:

  • RAD51 functions in a PALB2-scaffolded HR complex with BRCA2 and RAD51C

  • RAD50 operates within the MRN complex (MRE11-RAD50-NBS1)

  • These complex interactions may affect epitope accessibility

• Application-tailored antibody selection:

  • For co-immunoprecipitation: Antibodies that don't disrupt complex formation

  • For immunofluorescence: Antibodies that recognize native protein conformations

  • For chromatin immunoprecipitation: Antibodies compatible with crosslinking

• Experimental validation strategies:

  • Parallel detection of multiple complex components

  • Functional validation through activity assays

  • Knockdown/knockout controls to confirm specificity

• Advanced modeling applications:

  • Computational approaches can identify antibodies that recognize specific binding modes associated with complex formation or particular functional states

  • Biophysics-informed models can predict antibodies that discriminate between similar complexes or different functional states of the same complex

What considerations are important when using these antibodies to study DNA damage response?

The DNA damage response (DDR) presents unique challenges for antibody-based detection:

• Dynamic protein behavior:

  • RAD51 is recruited to DNA damage sites and forms visible foci during homologous recombination

  • RAD50, as part of the MRN complex, is among the first responders to double-strand breaks

  • These dynamics affect epitope accessibility and detection sensitivity

• Experimental design considerations:

  • Temporal analysis: Sample collection timing after damage induction

  • Spatial analysis: Subcellular localization changes during DDR

  • Quantitative analysis: Foci counting, intensity measurements

• Controls specific to DDR studies:

  • Positive controls: DNA damaging agent treatments (e.g., ionizing radiation, hydroxyurea)

  • Negative controls: DDR inhibitors or knockdown of upstream signaling components

  • Parallel markers: Co-staining with γH2AX or other established DDR markers

• Antibody selection for specific DDR contexts:

  • For detecting RAD51 filaments: Antibodies validated for immunofluorescence

  • For quantifying total vs. chromatin-bound protein: Fractionation-compatible antibodies

  • For detecting post-translational modifications: Modification-specific antibodies

How can antibody phage display technologies be leveraged to develop more specific reagents?

Phage display technology offers powerful approaches for developing highly specific antibodies:

• Library design and selection strategies:

  • Systematic variation of complementarity determining regions (CDRs), particularly CDR3

  • Selection against diverse combinations of ligands to identify specific binders

  • Counter-selection to remove non-specific binders

• High-throughput sequencing integration:

  • Monitoring antibody library composition at each selection step

  • Identifying enriched sequences associated with specific binding profiles

  • Quantifying selection pressure effects on antibody population evolution

• Computational model enhancement:

  • Training biophysics-informed models on phage display selection data

  • Associating distinct binding modes with specific ligands

  • Predicting and generating antibody variants with customized specificity profiles

• Experimental validation approaches:

  • Testing computationally designed antibodies not present in original libraries

  • Validating specificity profiles against multiple related ligands

  • Comparing experimental results with model predictions

This integrated approach has successfully demonstrated the "computational design of antibodies with customized specificity profiles, either with specific high affinity for a particular target ligand, or with cross-specificity for multiple target ligands" .

What are the latest advances in integrating computational modeling with antibody selection for complex targets?

Recent advances in computational-experimental integration have transformed antibody development:

• Biophysics-informed machine learning models:

  • Incorporating biophysical constraints improves model interpretability

  • Enabling prediction of properties beyond direct selection criteria

  • Offering quantitative insights into antibody-antigen interactions

• Multiple property inference:

  • Predicting specificity profiles from binding affinity measurements

  • Inferring thermal stability from selection experiments

  • Designing antibodies with customized combinations of properties

• Binding mode disentanglement:

  • Identifying different contributions to binding from single experiments

  • Associating distinct modes with specific ligands or epitopes

  • Enabling design of antibodies that discriminate between similar targets

• Experimental validation frameworks:

  • Training models on selection data from one ligand combination

  • Predicting outcomes for different ligand combinations

  • Generating and testing novel antibody variants

The combination of these approaches has "demonstrated the design of specific antibodies beyond those probed experimentally" and shown particular value "in a context where very similar epitopes need to be discriminated, and where these epitopes cannot be experimentally dissociated from other epitopes present in the selection" .

How will next-generation sequencing and machine learning continue to transform antibody research?

The integration of next-generation sequencing (NGS) and machine learning (ML) is revolutionizing antibody research:

• Beyond observed sequences:

  • NGS provides comprehensive antibody library composition data

  • ML models can predict properties for sequences not observed experimentally

  • This combination enables exploration of sequence space beyond physical library limitations

• Multi-property optimization:

  • Traditional approaches focus on single properties (binding, stability)

  • NGS+ML can infer multiple physical properties simultaneously

  • This allows optimization of complex property combinations (specificity, stability, solubility)

• Experimental-computational synergy:

  • Experimental selection provides training data

  • Computational models extend predictions beyond experimental constraints

  • Iterative cycles improve both experimental design and model accuracy

• Future applications:

  • Design of antibodies with unprecedented specificity discrimination

  • Prediction of cross-reactivity profiles for therapeutic antibodies

  • Optimization of antibody reagents for challenging research applications

  • Mitigation of experimental artifacts and biases in selection experiments

This integrated approach has broad applications beyond antibodies, offering "a powerful toolset for designing proteins with desired physical properties" that could transform protein engineering across multiple fields .

What statistical approaches are recommended for analyzing antibody specificity data?

When analyzing antibody specificity data, particularly from high-throughput experiments, several statistical approaches are recommended:

These statistical approaches enable researchers to "disentangle the different contributions to binding to several epitopes from a single experiment" and design antibodies with customized specificity profiles .

How can researchers ensure reproducibility when analyzing antibody performance across different experimental platforms?

Ensuring reproducibility across platforms requires systematic methodology:

• Standardized protocols:

  • Detailed documentation of experimental conditions

  • Consistent sample preparation methods

  • Standardized data collection parameters

• Cross-platform validation:

  • Testing antibodies in multiple applications (WB, IHC, IF, etc.)

  • Comparing results between different detection systems

  • Validating findings across independent laboratories

• Quantitative benchmarking:

  • Establishing standard curves with recombinant proteins

  • Using reference standards across experiments

  • Implementing normalization procedures for cross-platform comparison

• Computational model integration:

  • Training models on data from multiple platforms

  • Identifying platform-specific variables affecting performance

  • Developing correction factors for cross-platform normalization

This comprehensive approach enables researchers to achieve more consistent and reliable results when using antibodies across different experimental contexts.